Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as REGN668: Injection Rate 1
REGN668: Rate 1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | - |
| Group 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| REGN668: Injection Rate 1 | DRUG | Subjects will receive REGN668 via SC injection |
| REGN668: Injection Rate 2 | DRUG | Subjects will receive study drug via alternate delivery (if necessary) |
Inclusion Criteria: 1. Male or female subjects 18 to 55 years of age. 2. Body weight between 60 kg and 80 kg, body mass index between 20 and 30 kg/m2 inclusive. 3. NHV as evidenced by comprehensive clinical assessment (detailed medical history and complete physical examination). 4. Normal resting b...
REGN668 is an investigational small molecule developed by Regeneron Pharmaceuticals, Inc. It has been studied in a Phase 1 clinical trial in healthy adult volunteers in the United States. REGN668 is also known as REGN668: Injection Rate 1.
REGN668 is being developed by Regeneron Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker REGN. Regeneron sponsored the Phase 1 study of REGN668 conducted in the United States.
REGN668 is in Phase 1 development. Its only recorded clinical trial, NCT01484600, was a Phase 1 study that has been completed. REGN668 is investigational and has not been approved by the FDA.
REGN668 has been studied in one clinical trial, NCT01484600, titled "Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers." The Phase 1 trial enrolled 36 healthy volunteers in the United States and is completed.
Yes, REGN668: Injection Rate 1 is an alternative name for REGN668. Both names refer to the same investigational small molecule developed by Regeneron Pharmaceuticals, Inc. for subcutaneous administration.
The REGN668 Phase 1 trial, NCT01484600, was a randomized, controlled study that enrolled 36 healthy volunteers aged 18 years and older in the United States. It evaluated safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous REGN668 and is completed.